Johnson & Johnson - Search News

Johnson & Johnson's Spravato nasal spray okayed

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Fast Company on MSN · 1d

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,

ScienceAlert on MSN · 8h

FDA-Approved Nasal Spray For Depression Is First Of Its Kind

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called Spravato (esketamine),

Hindustan Times on MSN · 23h

Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat.

Cam Johnson, Nets blocking out trade rumors

Bleacher Report · 1d

NBA Rumors: Kings Not in Cam Johnson Talks, Will Aggressively Explore Trade Options

Don't expect the Sacramento Kings to swing a deal for Brooklyn Nets' wing Cam Johnson. According to NBA reporter Marc Stein, the Kings have been

The New York Times · 17h

Why Nets’ Cam Johnson is a coveted player as NBA trade deadline nears

Cam Johnson, the soon-to-be 29-year-old Brooklyn Nets wing, has been arguably their best player overall this season. Let’s explore what makes Johnson one of the hottest options on the trade market. Johnson is the 3-and-D prototype,

ClutchPoints · 15h

Cam Johnson, Nets blocking out trade rumors as deadline approaches

Cam Johnson and the Nets are doing their best to block out trade speculation with the Feb. 6 deadline approaching.

21h

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

14h

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Supply Chain4h

Podcast | How Healthcare Giant Johnson & Johnson Is Making Its Supply Chain Sustainable

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...

22h

Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

The Motley Fool1d

Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...